Axl and growth arrest-specific gene 6 are frequently overexpressed in human gliomas and predict poor prognosis in patients with glioblastoma multiforme

Clinical Cancer Research

Volumn 14, Issue 1, 2008, Pages 130-138

  Hutterer, Markus ^a,c   Knyazev, Pjotr ^c   Abate, Ariane ^a   Reschke, Markus ^c   Maier, Hans ^b   Stefanova, Nadia ^a   Knyazeva, Tatjana ^c   Barbieri, Verena ^a   Reindl, Markus ^a   Muigg, Armin ^a   Kostron, Herwig ^a   Stockhammer, Guenther ^a   Ullrich, Axel ^c,d  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b MEDICAL UNIVERSITY OF INNSBRUCK   (Austria)

^c MAX PLANCK INSTITUTE OF BIOCHEMISTRY   (Germany)

^d INSTITUTE OF MOLECULAR AND CELL BIOLOGY   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; GROWTH ARREST SPECIFIC PROTEIN 6; MESSENGER RNA; PROTEIN AXL; PROTEIN TYROSINE KINASE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; ASTROCYTE; BRAIN TISSUE; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CELLULAR DISTRIBUTION; CONTROLLED STUDY; FEMALE; GLIOBLASTOMA; GLIOMA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TISSUE MICROARRAY; TUMOR GROWTH;

BRAIN NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION; GLIOBLASTOMA; HUMANS; IMMUNOHISTOCHEMISTRY; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; ONCOGENE PROTEINS; PROGNOSIS; RECEPTOR PROTEIN-TYROSINE KINASES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SURVIVAL ANALYSIS; TISSUE ARRAY ANALYSIS;

EID: 40749123639     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-0862     Document Type: Article

References (42)

1. Kleihues P, Sobin LH. World Health Organization classification of tumors. Cancer 2000;88:2887.
2. DeAngelis LM. Brain tumors. N Engl J Med 2001;344:114-23.
3. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:987-96.
4. Janssen JW, Schulz AS, Steenvoorden AC, et al. A novel putative tyrosine kinase receptor with oncogenic potential. Oncogene 1991;6:2113-20.
5. O'Bryan JP, Frye RA, Cogswell PC, et al. axl, a transforming gene isolated from primary human myeloid leukemia cells, encodes a novel receptor tyrosine kinase. Mol Cell Biol 1991;11:5016-31.
6. Stoeckli ET, Landmesser LT. Axonin-1, Nr-CAM, and Ng-CAM play different roles in the in vivo guidance of chick commissural neurons. Neuron 1995;14:1165-79.
7. Manfioletti G, Brancolini C, Avanzi G, Schneider C. The protein encoded by a growth arrest-specific gene (gas6) is a new member of the vitamin K-dependent proteins related to protein S, a negative coregulator in the blood coagulation cascade. Mol Cell Biol 1993;13:4976-85.
8. Varnum BC, Young C, Elliott G, et al. Axl receptor tyrosine kinase stimulated by the vitamin K-dependent protein encoded by growth-arrest-specific gene 6. Nature 1995;373:623-6.
9. Hafizi S, Dahlback B. Signalling and functional diversity within the Axl subfamily of receptor tyrosine kinases. Cytokine Growth Factor Rev 2006;17:295-304.
10. Vajkoczy P, Knyazev P, Kunkel A, et al. Dominant-negative inhibition of the Axl receptor tyrosine kinase suppresses brain tumor cell growth and invasion and prolongs survival. Proc Natl Acad Sci U S A 2006;103:5799-804.
11. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanatephenol-chloroform extraction. Anal Biochem 1987;162:156-9.
12. Remmele W, Schicketanz KH. Immunohistochemical determination of estrogen and progesterone receptor content in human breast cancer. Computer-assisted image analysis (QIC score) versus subjective grading (IRS). Pathol Res Pract 1993;189:862-6.
13. Ballman KV, Buckner JC, Brown PD, et al. The relationship between six-month progression-free survival and 12-month overall survival end points for phase II trials in patients with glioblastoma multiforme. Neurooncol 2007;9:29-38.
14. Brat DJ, Castellano-Sanchez AA, Hunter SB, et al. Pseudopalisades in glioblastoma are hypoxic, express extracellular matrix proteases, and are formed by an actively migrating cell population. Cancer Res 2004;64:920-7.
15. Brat DJ, Van Meir EG. Vaso-occlusive and prothrombotic mechanisms associated with tumor hypoxia, necrosis, and accelerated growth in glioblastoma. Lab Invest 2004;84:397-405.
16. Budagian V, Bulanova E, Orinska Z, et al. Soluble Axl is generated by ADAM10-dependent cleavage and associates with Gas6 in mouse serum. Mol Cell Biol 2005;25:9324-39.
17. Bellosta P, Costa M, Lin DA, Basilico C. The receptor tyrosine kinase ARK mediates cell aggregation by homophilic binding. Mol Cell Biol 1995;15:614-25.
18. McCloskey P, Fridell YW, Attar E, et al. GAS6 mediates adhesion of cells expressing the receptor tyrosine kinase Axl. J Biol Chem 1997;272:23285-91.
19. Berens ME, Rief MD, Shapiro JR, et al. Proliferation and motility responses of primary and recurrent gliomas related to changes in epidermal growth factor receptor expression. J Neurooncol 1996;27:11-22.
20. 3 in small blood vessels of glioblastoma tumors. J Neuropathol Exp Neurol 1996;55:1143-9.
21. Mason CA, Edmondson JC, Hatten ME. The extending astroglial process: development of glial cell shape, the growing tip, and interactions with neurons. J Neurosci 1988;8:3124-34.
22. Chintala SK, Kyritsis AP, Mohan PM, et al. Altered actin cytoskeleton and inhibition of matrix metalloproteinase expression by vanadate and phenylarsine oxide, inhibitors of phosphotyrosine phosphatases: modulation of migration and invasion of human malignant glioma cells. Mol Carcinog 1999;26:274-85.
23. Takeuchi H, Sato K, Ido K, Kubota T. Mitotic activity of multinucleated giant cells with glial fibrillary acidic protein immunoreactivity in glioblastomas: an immunohistochemical double labeling study. J Neurooncol 2006;78:15-8.
24. Newton HB. Molecular neuro-oncology and development of targeted therapeutic strategies for brain tumors. Part 1. Growth factor and Ras signaling pathways. Expert Rev Anticancer Ther 2003;3:595-614.
25. Allen MP, Zeng C, Schneider K, et al. Growth arrest-specific gene 6 (Gas6)/adhesion related kinase (Ark) signaling promotes gonadotropin-releasing hormone neuronal survival via extracellular signal-regulated kinase (ERK) and Akt. Mol Endocrinol 1999;13:191-201.
26. Funakoshi H, Yonemasu T, Nakano T, Matumoto K, Nakamura T. Identification of Gas6, a putative ligand for Sky and Axl receptor tyrosine kinases, as a novel neurotrophic factor for hippocampal neurons. J Neurosci Res 2002;68:150-60.
27. Shankar SL, O'Guin K, Kim M, et al. Gas6/Axl signaling activates the phosphatidylinositol 3-kinase/Akt1 survival pathway to protect oligodendrocytes from tumor necrosis factor α-induced apoptosis. J Neurosci 2006;26:5638-48.
28. Yagami T, Ueda K, Asakura K, et al. Effect of Gas6 on secretory phospholipase A(2)-IIA-induced apoptosis in cortical neurons. Brain Res 2003;985:142-9.
29. Yagami T, Ueda K, Asakura K, et al. Gas6 rescues cortical neurons from amyloid β protein-induced apoptosis. Neuropharmacology 2002;43:1289-96.
30. Melaragno MG, Wuthrich DA, Poppa V, et al. Increased expression of Axl tyrosine kinase after vascular injury and regulation by G protein-coupled receptor agonists in rats. Circ Res 1998;83:697-704.
31. Fridell YW, Villa J, Jr., Attar EC, Liu ET. GAS6 induces Axl-mediated chemotaxis of vascular smooth muscle cells. J Biol Chem 1998;273:7123-6.
32. O'Donnell K, Harkes IC, Dougherty L, Wicks IP. Expression of receptor tyrosine kinase Axl and its ligand Gas6 in rheumatoid arthritis: evidence for a novel endothelial cell survival pathway. Am J Pathol 1999;154:1171-80.
33. D'Arcangelo D, Gaetano C, Capogrossi MC. Acidification prevents endothelial cell apoptosis by Axl activation. Circ Res 2002;91:e4-12.
34. Melaragno MG, Cavet ME, Yan C, et al. Gas6 inhibits apoptosis in vascular smooth muscle: role of Axl kinase and Akt. J Mol Cell Cardiol 2004;37:881-7.
35. Collett G, Wood A, Alexander MY, et al. Receptor tyrosine kinase Axl modulates the osteogenic differentiation of pericytes. Circ Res 2003;92:1123-9.
36. Holland SJ, Powell MJ, Franci C, et al. Multiple roles for the receptor tyrosine kinase axl in tumor formation. Cancer Res 2005;65:9294-303.
37. Korshunov VA, Mohan AM, Georger MA, Berk BC. Axl, a receptor tyrosine kinase, mediates flow-induced vascular remodeling. Circ Res 2006;98:1446-52.
38. Hailer NP, Wirjatijasa F, Roser N, et al. Astrocytic factors protect neuronal integrity and reduce microglial activation in an in vitro model of N-methyl-D-aspartate-induced excitotoxic injury in organotypic hippocampal slice cultures. Eur J Neurosci 2001;14:315-26.
39. Seguin R, Biernacki K, Rotondo RL, Prat A, Antel JP. Regulation and functional effects of monocyte migration across human brain-derived endothelial cells. J Neuropathol Exp Neurol 2003;62:412-9.
40. Abbott NJ, Ronnback L, Hansson E. Astrocyte-endothelial interactions at the blood-brain barrier. Nat Rev Neurosci 2006;7:41-53.
41. Batchelor TT, Sorensen AG, di Tomaso E, et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 2007;11:83-95.
42. Hutterer M, Gunsilius E, Stockhammer G. Molecular therapies for malignant glioma. Wien Med Wochenschr 2006;156:351-63.